Atomic-level Specificity of Claudin 6 Monoclonal Antibodies Isolated for Treating Solid Tumors

Publications

Apr 15

Written By Martin Lehr

2022_AACR_MPS Final1024_1.jpg

Martin Lehr

Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022